Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | HBB | P68871 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ENTPD1 | P49961 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15456809 | 1.00 | LMNA (0.69) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL15245119 | 1.00 | LMNA (0.69) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL29810829 | 0.99 | LMNA (0.70) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL14853626 | 0.94 | LMNA (0.67) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL15721814 | 0.93 | ENTPD1 (0.61) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL15305337 | 0.92 | SMN1; SMN2 (0.75) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL16543524 | 0.92 | SMN1; SMN2 (0.75) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL29810834 | 0.92 | SMN1; SMN2 (0.75) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL14613250 | 0.89 | PARG (0.69) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL14946175 | 0.88 | ENTPD1 (0.53) | LMNATP53HBBSMN1; SMN2ENTPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136711-A1 | SEMENOGELIN NEUTRALIZING ANTIBODY AND EPITOPE AND APPLICATION THEREOF | SHANGHAI BIOTROY BIOTECHNIQUE CO., LTD (CN) | 2025-05-01 | — | — | US | claimed |
| CN-118924887-A | HPV MRNA LNP vaccine | 南京吉迈生物技术有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | MODERNATX, INC. (US) | 2024-05-14 | — | — | US | claimed |
| US-11951120-B2 | Modification of gene transcription and translation efficiency by 5′UTR sequence variation | Nanjing GeneLeap Biotechnology Co., Ltd. | 2024-04-09 | — | — | US | claimed |
| US-20230310484-A1 | Modification of Gene Transcription and Translation Efficiency by 5'UTR Sequence Variation | Nanjing GeneLeap Biotechnology Co., Ltd. (CN) | 2023-10-05 | — | — | US | claimed |
| CN-116179549-A | Modification of gene transcription and translation efficiency by 5' UTR sequence variants | 南京吉迈生物技术有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-20230050143-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | MODERNATX, INC. (US) | 2023-02-16 | — | — | US | claimed |
| EP-4096715-A1 | COMPOSITIONS COMPRISING LINEAR POLYRIBONUCLEOTIDES FOR PROTEIN MODULATION AND USES THEREOF | Flagship Pioneering Innovations VI, LLC (US) | 2022-12-07 | — | — | EP | claimed |
| US-11389546-B2 | Heterologous UTR sequences for enhanced mRNA expression | MODERNATX, INC. (US) | 2022-07-19 | — | — | US | claimed |
| EP-4747380-A1 | MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE | CRISPR Therapeutics AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026107144-A1 | RNA SEQUENCE FOR EXPRESSING PROTEIN IN CARDIOMYOCYTES | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122070365-A | Systems and compositions comprising highly active trans-amplified replicase | 百欧恩泰欧洲股份公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-12606822-B2 | Synthetic modified RNA and uses thereof | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2026-04-21 | — | — | US | disclosed |
| WO-2022103839-A1 | RNA EDITING COMPOSITIONS AND USES THEREOF | SHAPE THERAPEUTICS INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| CN-114502204-A | RNA combinations and compositions with reduced immunostimulatory properties | 库尔维科公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114401942-A | Tris (hydroxymethyl) methylglycine and citrate esters | 川斯勒佰尔公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114381470-A | Artificial nucleic acid molecules | 库瑞瓦格股份公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3964576-A1 | MODIFIED MRNAS FOR VACCINE DEVELOPMENT | baseclick GmbH (DE) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022043551-A2 | MULTIVALENT NUCLEIC ACID BASED CORONAVIRUS VACCINES | CUREVAC AG (DE) | 2022-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11389546-B2 | Heterologous UTR sequences for enhanced mRNA expression | RNGTT, UPF1, RNMT | LMNA 1731/4885TP53 1521/4885HBB 2159/4885 |
| US-20230050143-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | RNGTT, UPF1, RNMT | LMNA 1731/4885TP53 1521/4885HBB 2159/4885 |
| US-12606822-B2 | Synthetic modified RNA and uses thereof | CES1, MAT1A, CPS1 | LMNA 2175/4885TP53 3042/4885HBB 3699/4885 |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | RNGTT, UPF1, RNMT | LMNA 1731/4885TP53 1521/4885HBB 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.